Fig. 3From: N-acetylglucosamine inhibits inflammation and neurodegeneration markers in multiple sclerosis: a mechanistic trialChange in serum cytokine levels with oral GlcNAc therapy. A–P Averaged cytokine levels before (visits 1–4), during (visits 5–8), and after (visits 9–11) GlcNAc treatment individually (A,C,E,G,I,K,M,O) or combined (B, D, F, H, J, L, N, P) as measured by sandwich ELISA. Only cytokine levels above the LLOQ were included in analysis. Error bars represent SEM. P value by linear mixed models (one-tailed) using all subjects who completed the studyBack to article page